Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Inclusion Criteria: * Age ≥ 18 years; * Pathologically confirmed marginal zone lymphoma; * Presence of evaluable lesions; * Meets indications for treatment: Fulfills the GELF criteria OR has disease-related clinical symptoms/organ function impairment; * Patients who are unsuitable for local radiotherapy, refuse local radiotherapy, or have disease progression after local therapy. Cases considered unsuitable for local radiotherapy include the following: Gastric MALT MZL, Ann Arbor stage I, that is H. pylori-negative, or H. pylori-positive gastric MALT MZL (Ann Arbor stage I) with poor response to H. pylori eradication therapy; Non-gastric MALT and nodal MZL in Ann Arbor non-contiguous stage II or stages III-IV; SMZL; Gastric MALT classified as Lugano II2, IIE, or IV stage; Patient intolerance to radiotherapy; Other MZL patients deemed unsuitable for local radiotherapy by the investigator. * ECOG score of 0-3; * Expected survival time ≥ 3 months; * Ability to provide signed informed consent. Exclusion Criteria: * Currently diagnosed with another malignant tumor; * Central nervous system involvement by lymphoma or transformation to a higher grade; * Allergy to any of the investigational drugs; * Active infection or uncontrolled HBV infection, HIV/AIDS, or other serious infectious diseases; * Pregnancy, lactating women, or subjects of childbearing potential unwilling to use contraception; * Other situations deemed by the investigator as unsuitable for participation in this trial.